UPSC Darpan

Health & Life SciencesGS2 · GS32 October 2026

Karnataka finds hospitals billing near MRP on drugs bought up to 52 times cheaper

Open in the app — quiz, notes, Mistake Vault हिंदी में पढ़ें

The news

Bengaluru. Karnataka has asked the Centre to curb steep mark-ups on cancer drugs, medical devices and hospital consumables, The Economic Times reports. Inspections by the State’s Food Safety and Drug Administration across hospitals, including cancer centres, found patients billed at or near the maximum retail price (MRP, the printed ceiling a seller may charge) although hospitals bought at heavily discounted institutional rates. Mark-ups ranged from 10 times to more than 52 times the acquisition cost in several cases, with anomalies in 253 medicines and consumables. Gufipol was procured at ₹86 against an MRP of ₹4,528; a Guficycline-50 injection at ₹160 against ₹7,110. The findings have gone to the Union Health Ministry and the National Pharmaceutical Pricing Authority (NPPA). What is new since the Supreme Court’s remark is State-collected evidence that the problem lies in the hospital, not only the factory.

The chain in one line: Companies print a high MRP but sell to hospitals cheaply → hospitals bill at MRP → admitted patients cannot shop around → Karnataka’s inspectors document 253 cases → the State asks the Centre and NPPA to act

Static syllabus linkage

  1. Drug prices are controlled by an order under the Essential Commodities Act. The Drugs (Prices Control) Order, 2013 is issued under the Essential Commodities Act, 1955. It fixes a ceiling price for “scheduled” medicines, those in the National List of Essential Medicines, at the simple average of brands with at least 1% market share; for other medicines it limits the annual MRP increase to 10%.
  2. NPPA fixes and enforces prices; trade margin caps are its sharper tool. The National Pharmaceutical Pricing Authority, set up in 1997 and now an attached office of the Department of Pharmaceuticals, fixes ceiling prices and recovers overcharges. In February 2019 it used its public-interest power under the order to cap the trade margin, the gap between the price to stockist and the MRP, at 30% for 42 non-scheduled anti-cancer medicines, pulling MRPs down towards real selling prices.

Why UPSC loves this

  1. Health financing and regulation are a steady GS2 theme. The GS2 line “issues relating to development and management of social sector/services relating to health” covers out-of-pocket spending. Questions here ask why price control fails to reach patients, and this card gives a concrete answer.

Prelims nuggets

  • The Drugs (Prices Control) Order, 2013 is issued under the Essential Commodities Act, 1955; its ceiling prices apply to medicines in the National List of Essential Medicines.
  • For non-scheduled medicines, a manufacturer may not raise the MRP by more than 10% in a year.
  • Trade margin rationalisation caps the gap between the price to stockist and the MRP; NPPA, under the Department of Pharmaceuticals, applied a 30% cap to 42 anti-cancer drugs in 2019.

Analysis

  1. Lens — Market and State: a hospital is not a market, so a price ceiling becomes a price target. A shopper can walk to another chemist; an admitted cancer patient cannot, and does not know what the hospital paid. This is information asymmetry with a captive buyer, and it lets the seller charge the most the law allows, so the MRP meant as a ceiling becomes the bill. The sound judgement: a market failure the State must fix, by making purchase prices visible.
  2. Companies inflate MRP because hospitals reward it. A brand with a higher MRP gives the hospital a bigger margin and so wins its order over a rival with an honest price; competition works backwards. Capping trade margins attacks this incentive directly, which is why the 2019 cancer-drug cap cut prices sharply. Counter-view: margins fund hospital pharmacies and cold chains, so a cap must leave a handling fee.
  3. Spurious and inflated drugs come from the same opaque chain. The Hindu reports that regulators tested 1,41,322 drug samples in 2025-26, checking what is inside the vial; nobody checks what the patient paid for it. Linking procurement invoices to patient bills would serve quality and price at once.

Possible Mains question

Price control in India regulates the factory gate but not the hospital bed. Comment with reference to recent findings on hospital drug mark-ups. (10 marks, 150 words)

Model approach

  1. Directive — Comment. Give a reasoned opinion with evidence and end with a clear view.
  2. Introduction — open with Karnataka’s 253 cases and the 52-times mark-up. About 20 words.
  3. The 2013 order caps the printed price, not the hospital’s margin. Ceiling prices for NLEM drugs, a 10% annual limit for others.
  4. A captive patient turns the ceiling into the bill. Draw a flowchart: factory price → institutional price → MRP → patient bill, marking where the gap arises.
  5. Trade margin caps work where tried. Value addition: NPPA’s 2019 cap of 30% on 42 anti-cancer drugs.
  6. Conclusion — extend margin caps to hospital-heavy drugs and print purchase price on bills. About 15 words.

Administrator's brainstorm

You are a State Drugs Controller who has found these mark-ups. What do you do before the Centre acts?

I would publish the 253 anomalies with purchase and billing prices so patients and insurers see the gap. I would ask hospitals empanelled under government insurance to bill these items at purchase price plus a fixed handling charge as a condition of empanelment. Any MRP that itself breaches the price order goes to NPPA for recovery.